10199-51-6Relevant articles and documents
New pyrazolium-carboxylates as structural analogues of the pseudo-cross-conjugated betainic alkaloid nigellicine
Schmidt, Andreas,Habeck, Tobias,Kindermann, Markus Karl,Nieger, Martin
, p. 5977 - 5982 (2003)
Pyrazolium-3-carboxylates were examined as relatives of the betainic alkaloid Nigellicine and as new examples of the sparsely populated class 16 of heterocyclic pseudo-cross-conjugated mesomeric betaines (PCCMB). The title compounds were prepared in a 4-step procedure starting from β-diketo compounds 8 which were cyclized with substituted hydrazines. The resulting isomeric pyrazole esters 9 and 10 were separated and subsequently quaternized with dimethyl sulfate in the presence of nitrobenzene to pyrazolium esters 11 and 12. Saponification was best accomplished in diluted sulfuric acid, which resulted in the formation of the pseudo-cross-conjugated mesomeric betaines 13 and 14 in one step. Protonation to the corresponding carboxylic acids required the treatment of the betaines with tetrafluoroboric acid in dichloromethane. The effect of negative solvatochromism proves the charge separation in the ground state of the molecules. X-ray crystallographic analyses, semiempirical calculations, and ESI mass spectrometric measurements were performed to gain knowledge about the phenomenon of pseudo-cross-conjugation.
N-hydroxyl-5-substituted-1H-pyrazol-3-formamide compound as well as preparation method and use thereof
-
Paragraph 0024; 0028; 0029, (2019/02/03)
The invention belongs to the field of medicine chemistry, and particularly relates to an N-hydroxyl-5-substituted-1H-pyrazol-3-formamide compound as well as a preparation method and use thereof. The specific structure of the compound is as shown in a formula I. The invention also provides a synthesis method of the compound in the formula I and inhibition activity thereof for acidic sphingomyelinase. The compound can be used for developing drugs for treating atherosclerosis (AS), diabetes, emphysema, pulmonary edema, pulmonary fibrosis, cystic fibrosis, chronic obstructive pulmonary disease, pulmonary arterial hypertension, non-alcoholic fatty liver disease, Alzheimers (AD), multiple sclerosis (MS), cerebral stroke and depression diseases. (the formula I is shown in the description).
Discovery and evaluation of Cav3.1-selective T-type calcium channel blockers
Bezen?on, Olivier,Remeň, Lubo?,Richard, Sylvia,Roch, Catherine,Kessler, Melanie,Moon, Richard,Mawet, Jacques,Ertel, Eric A.,Pfeifer, Thomas,Capeleto, Bruno
, p. 5322 - 5325 (2017/10/26)
We identified and characterized a series of pyrazole amides as potent, selective Cav3.1-blockers. This series culminated with the identification of pyrazole amides 5a and 12d, with excellent potencies and/or selectivities toward the Cav3.2- and Cav3.3-channels. This compound displays poor DMPK properties, making its use difficult for in vivo applications. Nevertheless, this compound as well as analogous ones are well-suited for in vitro studies.